{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:24:29Z","timestamp":1787901869521,"version":"build-2784847793"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"14","funder":[{"name":"FIS","award":["PI19\/00318"],"award-info":[{"award-number":["PI19\/00318"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi\/MEKi) in patients with brain metastatic BRAF V600E\/K\u2013mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical BRAF activation, highlighting the need for more effective therapeutic options. Aiming to address this clinical challenge, we characterized the activity of a potent, brain-penetrant paradox breaker BRAFi (compound 1a, C1a) as first-line therapy and following progression upon treatment with approved BRAFi and BRAFi\/MEKi therapies. C1a activity was evaluated in vitro and in vivo in melanoma cell lines and patient-derived models of BRAF V600E\u2013mutant melanoma brain metastases following relapse after treatment with BRAFi\/MEKi. C1a showed superior efficacy compared with approved BRAFi in both subcutaneous and brain metastatic models. Importantly, C1a manifested potent and prolonged antitumor activity even in models that progressed on BRAFi\/MEKi treatment. Analysis of mechanisms of resistance to C1a revealed MAPK reactivation under drug treatment as the predominant resistance-driving event in both subcutaneous and intracranial tumors. Specifically, BRAF kinase domain duplication was identified as a frequently occurring driver of resistance to C1a. Combination therapies of C1a and anti\u2013PD-1 antibody proved to significantly reduce disease recurrence. Collectively, these preclinical studies validate the outstanding antitumor activity of C1a in brain metastasis, support clinical investigation of this agent in patients pretreated with BRAFi\/MEKi, unveil genetic drivers of tumor escape from C1a, and identify a combinatorial treatment that achieves long-lasting responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A brain-penetrant BRAF inhibitor demonstrates potent activity in brain metastatic melanoma, even upon relapse following standard BRAF inhibitor therapy, supporting further investigation into its clinical utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-21-4152","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T12:47:11Z","timestamp":1652878031000},"page":"2552-2564","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis"],"prefix":"10.1158","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9260-448X","authenticated-orcid":false,"given":"Ester","family":"Bonfill-Teixidor","sequence":"first","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-6679","authenticated-orcid":false,"given":"Raffaella","family":"Iurlaro","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Handl","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wichmann","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Arias","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cuartas","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-954X","authenticated-orcid":false,"given":"Jasmin","family":"Emmenegger","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romagnani","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-5053","authenticated-orcid":false,"given":"Luca","family":"Mangano","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-4889","authenticated-orcid":false,"given":"Thomas","family":"Lorber","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-402X","authenticated-orcid":false,"given":"Marco","family":"Berrera","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-4255","authenticated-orcid":false,"given":"Christina","family":"Godfried Sie","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00f6chl","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Eckmann","sequence":"additional","affiliation":[{"name":"3Roche Pharma Research and Early Development pRED, Roche Innovation Center Munich, Penzberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romi","family":"Feddersen","sequence":"additional","affiliation":[{"name":"3Roche Pharma Research and Early Development pRED, Roche Innovation Center Munich, Penzberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-928X","authenticated-orcid":false,"given":"Martin","family":"Kornacker","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-8596","authenticated-orcid":false,"given":"Gabriel","family":"Schnetzler","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-9072","authenticated-orcid":false,"given":"Marta","family":"Cicuendez","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Cordero","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomaz E.","family":"Topczewski","sequence":"additional","affiliation":[{"name":"4Hospital Clinic, University of Barcelona and Institut d'Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Ferres-Pijoan","sequence":"additional","affiliation":[{"name":"4Hospital Clinic, University of Barcelona and Institut d'Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"4Hospital Clinic, University of Barcelona and Institut d'Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-0828","authenticated-orcid":false,"given":"Francisco","family":"Mart\u00ednez-Ricarte","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-7608","authenticated-orcid":false,"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Bischoff","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-2463","authenticated-orcid":false,"given":"Piergiorgio","family":"Pettazzoni","sequence":"additional","affiliation":[{"name":"2Roche Pharma Research and Early Development pRED, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-5974","authenticated-orcid":false,"given":"Joan","family":"Seoane","sequence":"additional","affiliation":[{"name":"1Preclinical and Translational Research Program-Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2025112417174484800_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025112417174484800_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdin.2020.10.013","article-title":"The global burden of skin cancer: a longitudinal analysis from the global burden of disease study, 1990\u20132017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"key":"2025112417174484800_bib3","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"key":"2025112417174484800_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025112417174484800_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","article-title":"Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies","volume":"18","author":"Vosoughi","year":"2018","journal-title":"BMC Cancer"},{"key":"2025112417174484800_bib6","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112417174484800_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112417174484800_bib8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025112417174484800_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"key":"2025112417174484800_bib10","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1038\/s41388-020-1263-y","article-title":"RAF kinase dimerization: implications for drug discovery and clinical outcomes","volume":"39","author":"Brummer","year":"2020","journal-title":"Oncogene"},{"key":"2025112417174484800_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"2025112417174484800_bib12","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025112417174484800_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"2025112417174484800_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025112417174484800_bib15","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025112417174484800_bib16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"2025112417174484800_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/1078-0432.CCR-21-2761","article-title":"Preclinical characterization of a next generation brain permeable, paradox breaker BRAF inhibitor","volume":"28","author":"Wichmann","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112417174484800_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/0008-5472.CAN-14-1854","article-title":"Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer","volume":"75","author":"Pettazzoni","year":"2015","journal-title":"Cancer Res"},{"key":"2025112417174484800_bib19","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2025112417174484800_bib20","first-page":"201178","article-title":"Scaling accurate genetic variant discovery to tens of thousands of samples","author":"Poplin","year":"2018","journal-title":"bioRxiv"},{"key":"2025112417174484800_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet"},{"key":"2025112417174484800_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2025112417174484800_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025112417174484800_bib24","first-page":"120295","article-title":"STAR-fusion: fast and accurate fusion transcript detection from RNA-Seq","volume-title":"bioRxiv","author":"Haas","year":"2017"},{"key":"2025112417174484800_bib25","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025112417174484800_bib26","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417174484800_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"key":"2025112417174484800_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.celrep.2016.05.064","article-title":"BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts","volume":"16","author":"Kemper","year":"2016","journal-title":"Cell Rep"},{"key":"2025112417174484800_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/pcmr.12591","article-title":"UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model","volume":"30","author":"Wang","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025112417174484800_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025112417174484800_bib31","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-16-1327","article-title":"Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases","volume":"22","author":"Osswald","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025112417174484800_bib32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112417174484800_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025112417174484800_bib34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cncr.32547","article-title":"Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series","volume":"126","author":"Holbrook","year":"2020","journal-title":"Cancer"},{"key":"2025112417174484800_bib35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat Med"},{"key":"2025112417174484800_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1535-7163.MCT-17-0705","article-title":"Response and resistance to paradox-breaking braf inhibitor in melanomas in vivo and ex vivo","volume":"17","author":"Hartsough","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2025112417174484800_bib37","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jid.2018.07.045","article-title":"Genetic abnormalities in large to giant congenital nevi: beyond NRAS mutations","volume":"139","author":"Martins da Silva","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025112417174484800_bib38","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-13-3270","article-title":"Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025112417174484800_bib39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.29825","article-title":"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy","volume":"138","author":"Ross","year":"2016","journal-title":"Int J Cancer"},{"key":"2025112417174484800_bib40","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat Med"},{"key":"2025112417174484800_bib41","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"2025112417174484800_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2020.12.004","article-title":"Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study","volume":"32","author":"Gogas","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-21-4152\/3150406\/can-21-4152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-21-4152\/3154994\/can-21-4152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/14\/2552\/3180044\/2552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/14\/2552\/3180044\/2552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:17:56Z","timestamp":1764022676000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/82\/14\/2552\/706948\/Activity-and-Resistance-of-a-Brain-Permeable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":42,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,7,18]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-21-4152","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22431899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22431896","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22431896.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22431899.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6514028.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6514028","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}